T-cell therapy yields objective response rate of 52% in lymphoma (DLBCL) patients
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn more »
The updated data from a phase II JULIET study showed that chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) achieved an objective response rate (ORR) of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
The 52% (95% CI, 41-62) ORR included a complete response (CR) rate of 40% and a partial response (PR) rate of 12%.
To find out more detail about the trial, and the results within subgroups, read the full article here.
